Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of NVG-291 in Healthy Subjects
NCT05308953Phase 1Completed
- Sponsor
- NervGen Pharma Corp.
- Start
- May 2021
- Primary completion
- Jun 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial of NVG-291 in spinal cord injury (SCI) (3 arms), sponsored by NervGen Pharma Corp. Primary endpoint: Adverse Events. Started May 2021; status: completed.
02
Drugs
NVG-291
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT05308953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05308953.